As professors struggle to recruit postdocs, calls for structural change in academia intensify
Some content has been removed for formatting reasons. Please view the original article for the best reading experience. Dmitry Kovalchuk/iStock When Jennifer Mason posted an ad for a postdoc position in early March, she was eager to have someone on board by April or May to tackle recently funded projects. Instead, it took 2 months to receive a single application. Since then, only two more have come in. “Money is just sitting there that isn’t being used … and there’s these projects that aren’t moving anywhere as a result,” says Mason, an assistant professor in genetics at Clemson U...
Source: ScienceNOW - June 13, 2022 Category: Science Source Type: news

Johnson & Johnson Releases 2021 Health for Humanity Report Highlighting Performance on ESG Priorities and Progress Against Public Commitments
NEW BRUNSWICK, N.J., June 8, 2022 - Johnson & Johnson (NYSE: JNJ) today published its 2021 Health for Humanity Report, which shares progress against its purpose-driven Health for Humanity 2025 Goals and serves as its annual disclosure on environmental, social and governance (ESG) performance. In year one, we have exceeded one Health for Humanity 2025 Goal and are on track to deliver against the remaining 20 goals."Events from the past two years have only reinforced our understanding of the critical importance of good health," said Joaquin Duato, Chief Executive Officer, Johnson & Johnson. "During these extraordinar...
Source: Johnson and Johnson - June 8, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

Credit Suisse Warns of Another Loss as Capital Recedes
The Swiss bank’s warning of a loss this quarter is an early sign that the disruption in financial markets since Russia invaded Ukraine is hitting activity among big international banks. #capitalrecedes (Source: Reuters: Health)
Source: Reuters: Health - June 8, 2022 Category: Consumer Health News Source Type: news

Updated Data for Janssen ’s Bispecific Teclistamab Suggest Continued Deep and Durable Responses in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
CHICAGO, ILLINOIS, June 5, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated efficacy and safety results from the teclistamab Phase 1/2 MajesTEC-1 study. Teclistamab is an investigational, off-the-shelf, T-cell redirecting bispecific antibody targeting B-cell maturation antigen (BCMA), which is being studied in patients with relapsed or refractory multiple myeloma (RRMM) who have received three or more prior lines of therapy.1 The data were featured as part of an oral session during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. Additional poster presentations f...
Source: Johnson and Johnson - June 5, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Longer-term Data from CARTITUDE-1 Study Demonstrate Continued Deep and Durable Responses to CARVYKTI ™ (ciltacabtagene autoleucel) in Heavily Pretreated Patients with Relapsed or Refractory Multiple Myeloma
CHICAGO, ILLINOIS, June 4, 2022 – – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the Phase 1b/2 CARTITUDE-1 study evaluating the efficacy and safety of CARVYKTI™ (ciltacabtagene autoleucel; cilta-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy. The study included patients with relapsed or refractory multiple myeloma (RRMM) who had received >3 lines of therapy including a proteasome inhibitor (PI), an anti-CD38 monoclonal antibody and an immunomodulatory agent (IMiD) or were double refractory to an IMiD and PI a...
Source: Johnson and Johnson - June 4, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Sectra reports revenue, sales growth in Q4, entire year
Sectra reported revenue growth for the fourth quarter and the entirety of th...Read more on AuntMinnie.comRelated Reading: Avicenna.AI secures distribution deal with Sectra Hospital groups in U.K. to install PACS software from Sectra Sectra appoints Jessica Holmquist as CFO Sectra inks deal with Medical University of South Carolina Health Sectra posts slight sales increase, profit dip in Q2 (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 3, 2022 Category: Radiology Source Type: news

Catholic Health points to Covid-19 surge, labor woes for $55M first-quarter loss
The health system reported greater losses in first quarter of 2022 than the previous year. (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - June 2, 2022 Category: Health Management Authors: Tracey Drury Source Type: news

New Data Show Patients Treated with First-in-Class TREMFYA ® (guselkumab) Achieve Durable Efficacy Across Joint and Axial Symptoms of Active Psoriatic Arthritis Through Two Years
SPRING HOUSE, PENNSYLVANIA, June 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from Phase 3 studies demonstrating patients treated with TREMFYA® (guselkumab) achieved consistent, long-term efficacy through two years across the domains of active psoriatic arthritis (PsA) – including joint, skin, enthesitis,a dactylitis,b spinal pain and disease severityc endpoints – irrespective of baseline characteristics.1 Further analyses showed TREMFYA also provided patients with sustained improvements in measures of health-related quality of life (HRQoL), including fatigue, pain...
Source: Johnson and Johnson - June 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA ® (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Digestive Disease Week® 2022
SPRING HOUSE, PENNSYLVANIA, May 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2 GALAXI 1 clinical trial of TREMFYA® (guselkumab) in adult patients with moderately to severely active Crohn’s disease (CD), and from three separate long-term pooled analyses of adult patients with ulcerative colitis (UC) and CD treated with STELARA® (ustekinumab).1,2,3,4 These data are being presented as oral and poster presentations and are among 29 Janssen abstracts presented during the Digestive Disease Week® (DDW) meeting taking place in person and virtually in San Di...
Source: Johnson and Johnson - May 24, 2022 Category: Pharmaceuticals Source Type: news

New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news

Björn Ulvaeus health: 'I have extremely few memories' - ABBA star on severe memory loss
BJ ÖRN ULVAEUS is the Swedish singer best known as one quarter of legendary musical group ABBA. Despite being one of the best-selling music acts in the history of popular music, a few years ago Ulvaeus revealed that he cannot remember half of his achievements, due to his memory loss. (Source: Daily Express - Health)
Source: Daily Express - Health - May 21, 2022 Category: Consumer Health News Source Type: news

Target posts a stunning drop in profit. Stock plunges
New York Target's earnings didn't hit the mark. Far from it. The retail giant reported a stunning 52% drop in profit for the first quarter, badly missing Wall Street's forecasts. The company... #retailgiant (Source: Reuters: Health)
Source: Reuters: Health - May 18, 2022 Category: Consumer Health News Source Type: news

Celtics vs. Heat: How Boston reverted to its worst habits in nightmare third quarter during Game 1 loss
Jayson Tatum turned the ball over six times in the quarter that doomed the Celtics on Tuesday night #jaysontatum #celtics (Source: Reuters: Health)
Source: Reuters: Health - May 18, 2022 Category: Consumer Health News Source Type: news

New Data Show TREMFYA ® (guselkumab) Binds to Both Inflammatory Cells and Interleukin (IL)-23, Supporting a Hypothesis for a Differentiated Mechanism from Risankizumab
SPRING HOUSE, PENNSYLVANIA, May 18, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the first results of the in vitro MODIF-Y studies, supporting a hypothesis that may differentiate the mechanism of first-in-class TREMFYA® (guselkumab) from risankizumab due to the ability of TREMFYA to bind to CD64 positive (CD64+) cells in addition to interleukin (IL)-23 — both of which are key components of the immune system. 1,2 These findings, which are being presented at the Society for Investigative Dermatology (SID) annual meeting May 18-21, 2022 in Portland, Oregon, demonstrate TREMFYA bind...
Source: Johnson and Johnson - May 18, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Walmart Earnings Are Dented by Higher Costs
The country’s largest retailer by revenue reported stronger sales in the first quarter but said that higher costs ate into its profits. #walmart (Source: Reuters: Health)
Source: Reuters: Health - May 17, 2022 Category: Consumer Health News Source Type: news